Expert Think Tank: Resources to Improve the Care of Patients With NSCLC and EGFR Mutations

Download All
Gain expert insights on challenges in and best practices for managing EGFR mutation–positive NSCLC with this comprehensive educational program, including expert-authored commentaries and text modules, an on-demand webcast of a CCO live webinar along with an FAQ audio podcast, a regularly updated downloadable teaching slideset, and downloadable clinical resource PDFs.
Edward B. Garon, MD, MS
Program Director
Edward B. Garon, MD, MS
Ryan D. Gentzler, MD, MS
Xiuning Le, MD, PhD
Joel W. Neal, MD, PhD
Zofia Piotrowska, MD, MHS
David Planchard, MD, PhD
person default
Jonathan Riess, MD, MS
Julia Rotow, MD
person default
Catherine A. Shu, MD
Mark A. Socinski, MD
Helena A. Yu, MD

ClinicalThought

Read this expert commentary to gain insights into the rationale and latest clinical evidence for combination strategies with EGFR TKIs for the first-line treatment of EGFR-mutated advanced NSCLC.

David Planchard, MD, PhD Released: December 3, 2021

What I want my colleagues to know about treating patients with advanced NSCLC and uncommon EGFR mutations, including future directions targeting these mutations.

Joel W. Neal, MD, PhD Released: May 20, 2022

In this commentary, a lung cancer expert highlights advances from ASCO 2022 in the management of EGFR-mutated NSCLC with acquired resistance to first-line EGFR TKI therapy using rational combination regimens composed of third-generation EGFR TKIs, EGFR monoclonal antibodies, bispecific antibodies, and antibody–drug conjugates.

person default Jonathan Riess, MD, MS Released: July 13, 2022

Adjuvant osimertinib has been approved for the treatment of patients with resectable early-stage EGFR-positive NSCLC for 2 years. A lung cancer expert discusses the continued DFS benefit and lack of OS data to date and reviews considerations for using adjuvant osimertinib in the clinic.

Edward B. Garon, MD, MS Released: October 24, 2022

Living Slideset

Review this slideset from a workshop series on optimal management of EGFR-mutated advanced NSCLC, including expert insights on promising investigational agents and combination therapy.

Edward B. Garon, MD, MS Helena A. Yu, MD Released: September 21, 2022

Modules

In this module, 5 lung cancer experts review oncology healthcare professional survey results on key educational needs for the multidisciplinary oncology team caring for patients with EGFR-mutated NSCLC, including discussion of standard-of-care practices, the latest clinical data, and ongoing challenges.

Edward B. Garon, MD, MS
Program Director
Xiuning Le, MD, PhD Zofia Piotrowska, MD, MHS Mark A. Socinski, MD Helena A. Yu, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: September 30, 2022 Expired: September 29, 2023

Downloadable slides capturing key data on standard-of-care practices and ongoing challenges for the multidisciplinary oncology team caring for patients with EGFR-mutated NSCLC as identified by 5 lung cancer experts.

Edward B. Garon, MD, MS
Program Director
Xiuning Le, MD, PhD Zofia Piotrowska, MD, MHS Mark A. Socinski, MD Helena A. Yu, MD
Released: September 30, 2022

Review an expert’s perspective on novel combination therapies and antibody–drug conjugates for the treatment of patients with EGFR-mutated advanced NSCLC in the first-line setting and beyond, including emerging data and key ongoing trials.

person default Catherine A. Shu, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: September 30, 2022 Expired: September 29, 2023

Download these slides for emerging data and a summary of key ongoing clinical trials evaluating novel combination therapies and antibody–drug conjugates for patients with EGFR-mutated advanced NSCLC in the first-line setting and beyond.

person default Catherine A. Shu, MD Released: September 30, 2022

PDF Clinical Summary Resource Guides

Download this focused resource for a quick guide to EGFR-targeted agents used in current practice for patients with advanced NSCLC and EGFR mutations, including exon 20 insertions.

Released: May 24, 2022

Download this clinical resource for expert recommendations from May 2022 on molecular testing for targetable genetic alterations in patients with advanced NSCLC.

Released: May 24, 2022

Download this short resource for a summary of ongoing clinical trials and active areas of research in the setting of EGFR-mutated NSCLC.

Released: May 24, 2022

On-Demand Webcast

Watch this on-demand webcast capturing a dynamic workshop led by an expert on managing EGFR-mutated NSCLC, including guidance on biomarker testing, treatment selection in the setting of early-stage and advanced disease, and future directions to improve outcomes for these patients

Julia Rotow, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 24, 2022 Expired: October 23, 2023

Podcast

Listen to experts answer questions from a live meeting series on optimizing the care of patients with EGFR-mutated non-small-cell lung cancer in the clinic today.

Ryan D. Gentzler, MD, MS person default Jonathan Riess, MD, MS Released: September 28, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings